Individual Study / Golestan Cohort Study

Golestan Cohort Study

Golestan Cohort Study

Initiatives -
Start Year
2004
End Year
2018
Funding
Tehran University/Medical Sciences (81/15 to R.M., Principal Investigator); Cambridge University (Cancer Research UK, C20/A5860 to B.P., N.D., Principal Investigators); the intramural research program of the NCI, National Institutes of Health; the IARC.
Visit Golestan Cohort Study

Members

Download
Investigators Contacts
  • Dr. Reza Malekzadeh
    Tehran University of Medical Sciences | TUMS
  • Dr. Paolo Boffetta
    Icahn School of Medicine at Mount Sinai
  • Dr. Prof. Farin Kamangar
    Morgan State University

Design

Study design
Population cohort
Follow Up
All participants are being followed up actively every 12 months. The follow-up is expected to continue for a minimum of 10 years.
Supplementary Information
https://dceg2.cancer.gov/gemshare/studies/GCS

Marker Paper

Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, Jafari E, Rakhshani N, Salahi R, Semnani S, Kamangar F, Abnet CC, Ponder B, Day N, Dawsey SM, Boffetta P, Malekzadeh R. Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010 Feb;39(1):52-9. doi: 10.1093/ije/dyp161. Epub 2009 Mar 30

PUBMED 19332502

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
50,045
Number of participants with biosamples
Supplementary Information
The study population is a sample of the Golestan population, aged 40-75 years.

Access

Availability of data and biosamples

Data
Biosamples
Other